IMAAVY
May 16, 2025
J&J Enters gMG Arena with IMAAVY Approval, Challenging AstraZeneca, Argenx, and UCB
The FDA has approved Johnson & Johnson’s anti-FcRn antibody, nipocalimab, for the treatment of generalized myasthenia gravis (gMG). This myasthenia gravis drug will be marketed under the name IMAAVY. Although J&J isn’t the first to receive FDA approval for an FcRn-blocking antibody in this indication, the c...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
